Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clioquinol - Gerolymatos Group/Prana Biotechnology

Drug Profile

Clioquinol - Gerolymatos Group/Prana Biotechnology

Alternative Names: Chloroiodoquine; Gero-46; Iodochlorhydroxyquin; Iodochlorhydroxyquinoline; PBT-1

Latest Information Update: 13 Apr 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gerolymatos Group; Prana Biotechnology
  • Class Antibacterials; Antidementias; Antifungals; Antiprotozoals; Hydroxyquinolines; Ionophores; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 11 Apr 2005 Discontinued - Phase-II for Alzheimer's disease in Australia (unspecified route)
  • 04 Jan 2005 Prana Biotechnology has received a CTA from the UK MHRA to initiate a phase II/III trial
  • 19 Apr 2004 Data from a media release have been added to the Alzheimer's disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top